Cohance Lifesciences Limited vs Abbott India Limited
Last updated: 4 November 2026
MoneyDock presents a comparative analysis between Cohance Lifesciences Limited (COHANCE.NS) and Abbott India Limited (ABBOTINDIA.NS). Both companies operate within the dynamic Indian pharmaceutical and healthcare sector, making them relevant for investors looking at this resilient industry. While Cohance Lifesciences likely focuses on specific segments of drug development or manufacturing, Abbott India, a subsidiary of the global pharmaceutical giant Abbott Laboratories, has a much broader portfolio covering pharmaceuticals, diagnostics, nutrition, and vascular products. This comparison will highlight key financial metrics to help investors understand their current market positions and potential trajectories, despite the limited available data for Cohance Lifesciences.
| Metric | Cohance Lifesciences Limited | Abbott India Limited |
|---|---|---|
| Current Price | ₹450.45 | ₹27120.00 |
| 52W High | ₹537.35 | ₹29025.00 |
| 52W Low | ₹279.90 | ₹25030.00 |
| 1-Year Return | -15.99% | -4.89% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
When comparing Cohance Lifesciences and Abbott India, several key aspects stand out, even with limited data. On valuation, both companies currently show 'N/A' for Trailing P/E and Market Cap, which makes a direct comparison challenging from this perspective. However, looking at their current prices and 52-week ranges, Abbott India trades at a significantly higher price point (₹27120.00 vs ₹450.45 for Cohance Lifesciences). This stark difference in price per share often reflects various factors including business scale, profitability, and investor perception, which are unfortunately not quantifiable with the provided 'N/A' for market cap.
Regarding returns, neither company has delivered positive returns over the past year. Cohance Lifesciences has seen a substantial decline of -15.99% in its 1-Year Return, indicating a period of significant underperformance. Abbott India, while also negative, has a comparatively less severe 1-Year Return of -4.89%. This suggests that Abbott India has demonstrated more resilience in its stock performance over the past year compared to Cohance Lifesciences, losing less value. From a purely returns perspective over this specific period, Abbott India appears to be the 'winner' as it has experienced a smaller loss.
For stability, we can infer some aspects from the 52-week ranges. Abbott India's current price of ₹27120.00 is closer to its 52W High of ₹29025.00 than its 52W Low of ₹25030.00, suggesting it has recovered somewhat from its lows or maintained a higher floor. Its range (approximately ₹4000) is a smaller percentage of its current price compared to Cohance Lifesciences. Cohance Lifesciences, with a current price of ₹450.45, is also closer to its 52W High of ₹537.35 than its 52W Low of ₹279.90. However, the difference between its high and low (approximately ₹250) is a larger proportion of its current price, potentially indicating higher volatility. Without Market Cap data, it's hard to assess the overall market confidence and long-term stability rigorously. Nevertheless, Abbott India's significantly higher price and generally tighter percentage fluctuation within its 52-week range might imply a more established and potentially stable operation compared to Cohance Lifesciences.
MoneyDock Verdict
For Aggressive Investors: Given the limited data, especially the absence of P/E and Market Cap, it's difficult to recommend either for purely aggressive, high-growth plays based solely on these numbers. However, Cohance Lifesciences' higher percentage decline in the last year (-15.99%) might suggest a higher risk/reward profile if one believes in a strong turnaround. But this is speculative without fundamental valuation metrics.
For Conservative Investors: Abbott India Limited appears to be the more conservative choice here. While it also shows a negative 1-year return, the -4.89% decline is considerably less than Cohance Lifesciences' -15.99%. Its higher price point and presumably larger, more established operations (implied by the global brand) typically align better with conservative investment strategies looking for relative stability, even in downturns.
For Long-Term SIP Investors: Both companies are in the healthcare sector, which generally has long-term growth potential in India. For a long-term SIP, Abbott India, with its comparatively smaller 1-year loss and potential for greater inherent stability as part of a global entity, might be a more suitable option to average into over time. Cohance Lifesciences, with its higher volatility and more significant recent underperformance, would require deeper fundamental research beyond these numbers to justify a long-term SIP commitment.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.